Camurus AB

Camurus AB

Health CarePharmaceuticals & Biotechnology
  • Price (SEK)70.20
  • Today's Change-0.40 / -0.57%
  • Shares traded10.48k
  • 1 Year change-24.83%
  • Beta1.3659
Data delayed at least 15 minutes, as of Jun 26 2019 17:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.

  • Revenue in SEK (TTM)53.18m
  • Net income in SEK-266.03m
  • Incorporated--
  • Employees103.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Alligator Bioscience AB26.22m-152.22m1.87bn56.00--4.40--71.19-2.13-2.130.36735.940.0492--19.28476,800.00-28.53---29.99-------580.47------0.0465---52.60---135.33------
Calliditas Therapeutics AB0.00-136.37m1.91bn13.00--3.64-----6.64-6.640.0016.440.00----0.00-40.82---44.93--------------0.00-------52.14------
Nordic Nanovector ASA0.00-368.16m2.24bn45.00--3.79-----6.75-6.750.008.860.00----0.00-54.52-34.38-62.03-38.09-------73,984.18----0.0125---100.00---14.96--48.77--
Infant Bacterial Therapeutics AB0.00-32.15m2.56bn8.00--4.71-----2.86-2.860.0049.530.00----0.00-5.55-17.29-5.61-18.00-------28,727.13---32.950.00---100.00---12.31------
Orexo AB817.70m177.90m2.58bn131.0014.285.0612.333.085.095.0923.3814.370.68060.79843.486,338,760.0014.81-1.4423.70-2.1081.8177.8021.76-2.281.81--0.4375--21.6612.77494.40---43.66--
Immunovia AB (publ)286.60k-95.60m2.83bn46.00--7.55--10,151.55-5.02-5.020.01522.260.0008--16.866,368.89-26.39-17.94-27.94-18.78-15,583.15-5,071.06-33,355.42-13,304.19----0.0729--123.28-22.36-91.32--81.72--
Camurus AB53.18m-266.03m3.50bn103.00--6.24--65.86-6.28-6.281.2511.700.09340.891815.82565,702.10-46.70---56.93--84.44---500.29--3.67-573.050.0473---9.18---23.14------
IRLAB Therapeutics AB18.00k-75.97m3.56bn26.00--18.34--198,033.60-1.93-1.930.00054.840.0001--0.004720.00-41.94---44.95-------422,055.60-----274.250.0285---83.49---31.79------
Oriola Oyj16.46bn117.07m3.77bn2.63k33.382.339.340.23520.06070.06078.600.86891.585.217.36576,903.201.123.513.7711.3122.3421.430.7112.170.3596.040.590247.581.60-0.8477-51.15-5.89-5.36--
Data as of Jun 26 2019. Currency figures normalised to Camurus AB's reporting currency: Swedish Krona SEK

Institutional shareholders

22.09%Per cent of shares held by top holders
HolderShares% Held
Max Mitteregger Kapitalf�rvaltning ABas of 30 Apr 20194.65m9.70%
Fj�rde AP-fondenas of 30 Apr 20193.00m6.25%
Catella Fondf�rvaltning ABas of 31 May 2019960.91k2.00%
Swedbank Robur Fonder ABas of 31 May 2019883.07k1.84%
Enter Fonder ABas of 31 Dec 2018443.32k0.92%
Xact Kapitalf�rvaltning ABas of 31 May 2019248.85k0.52%
SEB Investment Management ABas of 31 Dec 2018193.69k0.40%
Andra AP-fondenas of 30 Jun 2018158.03k0.33%
Nordic Cross Asset Management ABas of 20 Jun 201933.98k0.07%
Skandia Investment Management ABas of 30 Apr 201923.80k0.05%
More ▼
Data from 31 Dec 2016 - 20 Jun 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.